目的 觀察木香順氣丸聯(lián)合莫沙必利治療便秘型腸易激綜合征的療效及安全性。方法 選取2013年2月—2015年2月在遼寧省人民醫(yī)院消化內(nèi)科就診的便秘型腸易激綜合征患者148例,隨機分為治療組和對照組,每組各74例。對照組單用枸櫞酸莫沙必利分散片,5 mg/次,3次/d。治療組用枸櫞酸莫沙必利分散片5 mg/次,3次/d,木香順氣丸6 g/次,3次/d,均餐前30 min服用。兩組療程均為4周。比較了兩組癥狀改善情況、SF-36生活質(zhì)量、臨床療效及不良反應(yīng)。結(jié)果 治療后,兩組單項癥狀評分與治療前比較差異均具有統(tǒng)計學(xué)意義(P <0.01、0.05)。治療組在腹痛或不適、腹脹、排便頻率、大便性狀、排便異常(排便困難、排便不盡感)及精神問題方面癥狀改善明顯優(yōu)于對照組(P <0.05)。治療后,兩組癥狀總積分均明顯降低(P <0.01、0.05),兩組癥狀總積分比較差異具有統(tǒng)計學(xué)意義(P <0.05)。治療后各類腸易激綜合征患者的SF-36生活質(zhì)量得分均高于對照組,其中軀體疼痛、總體健康、活力、社會功能、情感職能和精神健康維度的治療后積分與對照組比較差異具有統(tǒng)計學(xué)意義(P <0.05)。治療后,治療組總有效率為94.59%,對照組總有效率為83.78%,總有效率組間比較差異具有統(tǒng)計學(xué)意義(P <0.05)。兩組患者在治療前后未發(fā)現(xiàn)藥物相關(guān)不良反應(yīng)。結(jié)論 木香順氣丸聯(lián)合莫沙必利治療便秘型腸易激綜合征可有效改善臨床癥狀,提高生活質(zhì)量,且具有良好的安全性,具有一定的臨床推廣價值。

Objective To investigate the effect and safety of Muxiang Shunqi Pills combined with mosapride in treatment of constipation-predominant irritable bowel syndrome. Methods Patients (148 cases) with constipation-predominant irritable bowel syndrome from Department of Gastroenterology in The People's Hospital of Liaoning Province from February 2013 to February 2015 were randomly divided into control and treatment groups. Each group had 74 cases. Patients in control group were singly po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. Patients in treatment group were po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. At the same time, Muxiang Shunqi Pills were given 30 min before meals, 6 g/time, three times daily. Two groups were treated for four weeks. Symptoms improvement, SF-36 life quality, clinical effect, and adverse reactions in two groups were compared. Results After treatment, the symptom scores in the two groups had statistically significant difference, and the difference was statistically significant in the same group (P < 0.05, 0.01). Abdominal pain or discomfort, abdominal distension, defecation frequency, stool traits, abnormal defecation (defecation difficulties and defecation), and mental symptoms of treatment group significantly improved better than those in the control group, with significant differences between two groups (P < 0.05). After treatment, the total scores in two groups were significantly reduced, and the difference was statistically significant in two groups (P < 0.05). After treatment, SF-36 life quality scores in the treatment group were higher than those of control group, and bodily pain, general health, vitality, social functioning, role-emotional, and mental health of treatment group significantly improved better than those in the control group, with significant differences between two groups (P < 0.05). After treatment, the efficacies in the control and treatment groups were 83.78% and 94.59%, respectively, and there were differences between two groups (P < 0.05). There were no adverse reactions in the two groups. Conclusion Muxiang Shunqi Pills combined with mosapride in treatment of constipation-predominant irritable bowel syndrome can improve clinical effect and quality of life, and has good safety, which has a certain clinical application value.